Skip to main content
Signal8
Launch Terminal

Altimmune, Inc. (ALT)

Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate, through Phase 2 clinical trials. This therapy is designed for individuals suffering from chronic hepatitis B virus infection. The enterprise, initially named Vaxin Inc., officially adopted the Altimmune, Inc. moniker in September 2015. Established in 1997, the company maintains its corporate headquarters in Gaithersburg, Maryland.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Altimmune, Inc. logo

Altimmune, Inc.

NASDAQ:ALTHealthcare
-4.67%$2.04
AH$2.07+1.47%vs close
Mkt Cap$396.82M
Float190.59M
O/S194.52M
Vol
$ Vol
RVOL
Inst Own77.2%
SI22.2%
Earnings
Dilution
Altimmune, Inc. logoNASDAQ:ALT$2.04-4.67%
Phase Distribution
28 lead-sponsored trials·2 active·22 completed
Phase 116
Phase 29
Phase 31
Phase 41
Not applicable1
Status Overview
Recruiting1
Active, not recruiting1
Completed22
Stopped4

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Status
Phase
  • Phase 4
    Completed

    Immune Response Following Seasonal Influenza Vaccination

    Licensed seasonal influenza vaccine

    Influenza

    Enrollment
    20
    Start
    May 2017
    Primary Completion
    Nov 2017
    Completion
    Jun 2018
    NCT03163342
  • Phase 3
    Recruiting

    Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASH

    Pemvidutide

    Metabolic Dysfunction-Associated Steatohepatitis (MASH)

    Enrollment
    1,800
    Start
    Jul 2026
    Primary Completion
    Dec 2028est.
    Completion
    Dec 2032est.
    NCT07795164
  • Phase 2
    Completed

    Phase II Study of Range and Schedule of rPA Doses

    rPA vaccine containing alhydrogel

    Prevention of Bacillus Anthracis (Anthrax) Infection

    Enrollment
    415
    Start
    Mar 2005
    Primary Completion
    Jan 2007
    Completion
    Feb 2007
    NCT00170456
  • Phase 2
    Completed

    Safety, Tolerability and Immunogenicity of Recombinant Anthrax Vaccine Compared With Anthrax Vaccine Adsorbed

    AVA, rPA vaccine containing alhydrogel

    Bacillus Anthracis (Anthrax)

    Enrollment
    226
    Start
    Mar 2005
    Primary Completion
    Feb 2007
    Completion
    Feb 2007
    NCT00170469
  • Phase 2
    Completed

    Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAX

    NasoVAX

    Influenza

    Enrollment
    60
    Start
    Sep 2017
    Primary Completion
    Mar 2018
    Completion
    Jun 2018
    NCT03232567
  • Phase 2
    Terminated

    NasoVAX in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19)

    NasoVAX

    Coronavirus Infection

    Enrollment
    48
    Start
    Oct 2020
    Primary Completion
    Feb 2021
    Completion
    Feb 2021
    NCT04442230
  • Phase 2
    Terminated

    HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB)

    HepTcell, Placebo

    Hepatitis B, Chronic

    Enrollment
    87
    Start
    Dec 2020
    Primary Completion
    Mar 2024
    Completion
    Apr 2024
    NCT04684914
  • Phase 2
    Completed

    Efficacy and Safety of ALT-801 in the Treatment of Obesity

    ALT-801

    Obesity/Overweight

    Enrollment
    391
    Start
    Mar 2022
    Primary Completion
    Sep 2023
    Completion
    Sep 2023
    NCT05295875
  • Phase 2
    Completed

    IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH)

    Pemvidutide, Placebo

    Non-Alcoholic Steatohepatitis (NASH)

    Enrollment
    212
    Start
    Jul 2023
    Primary Completion
    Nov 2025
    Completion
    Nov 2025
    NCT05989711
  • Phase 2
    Completed

    RECLAIM STUDY: Phase 2 Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight

    Pemvidutide

    Alcohol Use Disorder (AUD)

    Enrollment
    100
    Start
    May 2025
    Primary Completion
    Jul 2026
    Completion
    Jul 2026
    NCT06987513
  • Phase 2
    Active, not recruiting

    RESTORE TRIAL: Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)

    Pemvidutide

    Alcohol-associated Liver Disease

    Enrollment
    121
    Start
    Jun 2025
    Primary Completion
    Sep 2027est.
    Completion
    Sep 2027est.
    NCT07009860
  • Phase 1
    Completed

    One Year Study to Evaluate Three Different Adjuvanted Doses of the Recombinant Plague Vaccine (rF1 and rV Antigens)

    Alhydrogel, rF1 and rV protein antigens

    Plague

    Enrollment
    123
    Start
    Oct 2005
    Primary Completion
    Apr 2007
    Completion
    Apr 2007
    NCT00246467
  • Phase 1
    Completed

    First Time in Human Study of Protexia

    Protexia, Protexia

    Intervention for Nerve Agent Exposure

    Enrollment
    33
    Start
    Sep 2008
    Primary Completion
    Jul 2009
    Completion
    Nov 2009
    NCT00744146
  • Phase 1
    Completed

    Safety and Immunogenicity Study of Adenovirus-vectored, Intranasal Pandemic Influenza Vaccine.

    Pandemic Influenza Vaccine, Placebo

    Influenza A Subtype H5N1 Infection

    Enrollment
    48
    Start
    Oct 2008
    Primary Completion
    Sep 2009
    Completion
    Dec 2011
    NCT00755703
  • Phase 1
    Suspended

    Ph1 Study of Valortim and Ciprofloxacin in Humans

    Ciprofloxacin and Valortim, Placebo Antibiotic and Valortim

    Anthrax

    Enrollment
    26
    Start
    Aug 2009
    Primary Completion
    Feb 2010est.
    Completion
    Jul 2010est.
    NCT00964561
  • Phase 1
    Terminated

    Ph1 Study of Valortim and Doxycycline in Humans

    Doxycycline and Valortim, Placebo Antibiotic and Valortim

    Anthrax

    Enrollment
    24
    Start
    Jul 2009
    Primary Completion
    Oct 2009
    Completion
    Dec 2009
    NCT00964834
  • Phase 1
    Completed

    Study of Valortim® (MDX-1303) and Its Selected Formulation Components Percutaneous Use

    Valortim and selected Components, Valortim and Selected Components

    Allergic Reactions

    Enrollment
    5
    Start
    Jul 2010
    Primary Completion
    Aug 2010
    Completion
    Sep 2010
    NCT01204866
  • Phase 1
    Completed

    Dose Escalation Study of Valortim® (MDX-1303) Administered Intravenously (IV) in Healthy, Normal Subjects

    Normal Saline for Injection, MDX1303

    Anthrax

    Enrollment
    28
    Start
    Dec 2010
    Primary Completion
    Aug 2011
    Completion
    Dec 2011
    NCT01265745
  • Phase 1
    Completed

    Phase I Safety and Immunogenicity of FP-02.2 in Chronic Hepatitis B

    FP-02.2 Vaccine

    Hepatitis B

    Enrollment
    61
    Start
    Jul 2015
    Primary Completion
    Oct 2017
    Completion
    Jun 2018
    NCT02496897
  • Phase 1
    Completed

    NasoShield Study of Safety and Immunogenicity

    NasoShield, BioThrax

    Healthy Volunteers

    Enrollment
    145
    Start
    Jan 2018
    Primary Completion
    May 2019
    Completion
    May 2019
    NCT03352466
  • Phase 1
    Completed

    NasoShield in Healthy Adults to Study Safety and Immunogenicity

    NasoShield

    Healthy Volunteers

    Enrollment
    43
    Start
    Jun 2020
    Primary Completion
    Mar 2021
    Completion
    Mar 2021
    NCT04415749
  • Phase 1
    Completed

    ALT-801 (Pemvidutide) in Healthy Overweight and Obese Volunteers to Study Safety and Tolerability

    ALT-801

    Obesity, Nonalcoholic Steatohepatitis

    Enrollment
    100
    Start
    Nov 2020
    Primary Completion
    Oct 2021
    Completion
    Oct 2021
    NCT04561245
  • Phase 1
    Completed

    Safety and Immunogenicity of AdCOVID in Healthy Adults (COVID-19 Vaccine Study)

    AdCOVID

    Healthy Volunteers

    Enrollment
    92
    Start
    Feb 2021
    Primary Completion
    Dec 2021
    Completion
    Dec 2022
    NCT04679909
  • Phase 1
    Completed

    Pemvidutide (ALT-801) DDI Study in Healthy Volunteers

    Pemvidutide, Metformin

    NASH - Nonalcoholic Steatohepatitis

    Enrollment
    40
    Start
    Sep 2021
    Primary Completion
    May 2022
    Completion
    May 2022
    NCT04972396
  • Phase 1
    Completed

    ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)

    ALT-801

    Non-Alcoholic Fatty Liver Disease

    Enrollment
    95
    Start
    Sep 2021
    Primary Completion
    Aug 2022
    Completion
    Aug 2022
    NCT05006885

1-25 of 28

Search ClinicalTrials.gov for “Altimmune”